Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer-Reference-Cited by-同舟云学术

Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer

Published:2024-08-23 Issue: Volume: Page:
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Gunasekharan Vignesh,Lin Hao-Kuen,Marczyk Michal,Rios-Hoyo Alejandro,Campos Gerson Espinoza,Shan Naing Lin,Ahmed Mostafa,Umlauf Sheila,Gareiss Peter,Raaisa Raaisa,Williams Richard,Cardone Rebecca,Siebel Stephan,Kibbey Richard,Surovtseva Yulia V.,Pusztai Lajos

Funder

Lion Heart Foundation grant

Spanish Society of Medical Oncology

Breast Cancer Research Foundation investigator award

Susan Komen Leadership Grant

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10549-024-07462-z.pdf

Reference27 articles.

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

2. Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R et al (2022) Comprehensive analysis of metabolic isozyme targets in cancer. Cancer Res 82(9):1698–1711

3. Ureta T (1978) The role of isozymes in metabolism: a model of metabolic pathways as the basis for the biological role of isozymes. Curr Top Cell Regul 13:233–258

4. Ononye SN, Shi W, Wali VB, Aktas B, Jiang T, Hatzis C, Pusztai L (2014) Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets. Breast Cancer Res Treat 148(3):477–488

5. Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ et al (2013) A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell 24(2):182–196